NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
All content for AUAUniversity is the property of American Urological Association and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
MIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Jen-Jane Liu, MD, FACS
CME Available: auau.auanet.org/node/44077
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.
2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.
3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.
AUAUniversity
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
